[Investigation of prognostic factor and treatment mode for undifferentiated cervical carcinoma].
OBJECTIVE
To analyse the prognostic factor and investigate the treatment mode for undifferentiated cervical carcinoma.


METHODS
The recurrent rate, the metastatic rate and the survival rate were analysed retrospectively for 146 patients with stage I-II cervical carcinoma of poor differentiation treated with radical operation, operation/chemotherapy, operation/radiotherapy, operation/chemotherapy/radiotherapy from Jan. 1990 to Oct. 1998.


RESULTS
The recurrent rate of patients treated with radical operation/chemotherapy (18.18%) or radical operation/radiotherapy (24.32%) was lower than that of patients only treated with radical operation (36.36%) or operation/chemotherapy/radiotherapy (42.11%) for the cases of stage II or deep muscle invasion (P < 0.05). The recurrent rate of patients treated with radical operation/radiotherapy (22.22%) was lower than that of patients only treated with radical operation (2/2) for the cases with local lymphaden positive (P < 0.05). The investigation also showed that the distant metastatic rate of patients treated with radical operation/chemotherapy was 0.00%, which was lower than that of patients treated with radical operation 5.56% (P < 0.05). The 3-year survival rate was 100.00% and 88.53% respectively for the cases only treated with radical operation/chemotherapy or operation/radiotherapy; and it was lower for the cases treated with radical operation 76.74% (P < 0.05).


CONCLUSIONS
The prognosis of undifferentiated cervical carcinoma is related to the lymph node metastasis, the International Federation of Gynecology and Obstetrics stage and the treatment methods. The local recurrent rate and distant metastasis might be reduced by 2 courses of chemotherapy or radiotherapy post-operatively. The recurrent rate could not be reduced effectively by the combination therapy of operation/chemotherapy/radiotherapy.
Zhang
Y
Y
Department of Gynecology, Cancer Center, Sun Yat-sen University of Medical Sciences, Guangzhou 510060, China.
Li
M
M
Wang
H
H
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002277:Carcinoma / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents; D003520:Cyclophosphamide